ACTIVE TRIALS- METHODIST DALLAS LIVER INSTITUTE			
PI	**Sponsor**	**Short Title**	**Study Title**
Castillo	Johns Hopkins	APOLLO (034.IND.2016.D)	A prospective observational study of HIV+ deceased donor (HIVDD) solid organ transplant for HIV+ recipients **(HOPE)**
Pagadala	CymaBay Therapeutics, Inc.	CB8025-21629	An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
Nazario	Novartis	CLJN452A2202	A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH)
Barnes	Enanta Pharmaceuticals	EDP 305-201	A phase 2 dose ranging, randomized, double blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and efficacy of edp-305 in subjects with primary biliary cholangitis (pbc) with or without an inadequate response to ursodeoxycholic acid (udca)
Mantry	Genfit	GFT505-315-1	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Pagadala	GlaxoSmithKline (GSK)	GSK 201000	A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis. (GLIMMER: GSK2330672 trial of Ibat inhibition with Multidose Measurement for Evaluation of Response).
Mantry	HepQuant	HQ-US-SHUNT-1701	Hepquant
Mantry	Conatus Pharmaceuticals Inc.	IDN-6556-17	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Mantry	INTERCEPT	747-303	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Mantry	INTERCEPT	747-304	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Eficacy and Safety of Obeticholic-Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (REVERSE Study)
Pagadala	BRISTOL MYERS SQUIBB (BMS)	MB-130-68	Phase 3, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of bms-986036 (peg-fgf21) in adults with nonalcoholic steatohepatitis (nash) and stage 3 liver fibrosis
Mantry	BRISTOL MYERS SQUIBB (BMS)	MB-130-69	A phase 3, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of bms-986036 (peg-fgf21) in adults with nonalcoholic steatohepatitis (nash) and compensated liver cirrhosis
Barnes	Octeta/Cirius	MSDC-0602K-C009NASH	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients with NASH (EMMINENCE™)

Mantry	Tobira Therapeutics	STELLARIS: 3152-301-002	STELLARIS: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc in Adult Subjects with Nonalcoholic Steatohepatitis and Liver Fibrosis
Mantry	Synlogic, Inc.	SYNB1020-CP-002	A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1020 in Hepatic Insufficiency and Cirrhosis Patients with Hyperammonemia
Mantry	Synlogic, Inc.	SYNB1020-CP-005	Establishing the normal range of fasting venous ammonia level in healthy volunteers
Mantry	TARGET PharmaSolutions	TARGET-HCC	A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Mantry	Valeant	RNHE2041	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)